First FDA approved subcutaneous implantable defibrillator available for patients

Sudden cardiac arrest (SCA) is a condition in which the heart suddenly stops pumping blood. When this occurs, blood stops flowing to the brain and other major organs. Recent estimates show that approximately 850,000 people in the United States are at risk of SCA, and most of the people who have SCA, die from it. But, rapid treatment of SCA by using an implantable defibrillator can be lifesaving.

On September 28th, 2012, the FDA approved the world's first totally subcutaneous implantable defibrillator (S-ICD). Northwestern's Bluhm Cardiovascular Institute is one of the first 20 institutions in the country to have access to this technology. Since FDA approval, the Bluhm Cardiovascular Institute is one of the first ten places to implant in the U.S.

"The S-ICD system provides physicians with a new treatment option for patients who are at risk of ," said Bradley Knight, MD, electrophysiologist and medical director of the Center for . "The system sits entirely below the skin without requiring the need for placing wires in the heart, which leaves the heart and blood vessels untouched."

The Boston Scientific S-ICD® System has two main components. One is called the pulse generator, which powers the system, monitors and delivers a shock if needed. The other main component is the electrode. This enables the device to sense the heart rhythm and deliver shocks when necessary. Both are implanted just under the skin, providing protection without touching the heart and reliable without transvenous wires.

"Patients who previously could not undergo the implantation of a transvenous defibrillator, now have a device option to protect them from deadly arrhythmias," said Dr. Knight.

The S-ICD system is commercially available in many countries in Europe as well as New Zealand. More than 1,400 devices have been implanted in patients around the world.

add to favorites email to friend print save as pdf

Related Stories

US approves less-invasive heart defibrillator

Sep 29, 2012

(AP)—The U.S. Food and Drug Administration says it has approved a first-of-a-kind heart-zapping implant from Boston Scientific that that does not directly touch the heart.

Recommended for you

NT-proBNP modestly improves CVD risk prediction in women

19 hours ago

(HealthDay)—N-terminal pro-B-type natriuretic peptide (NT-proBNP) modestly improves cardiovascular disease (CVD) risk prediction for women, according to a study published in the Oct. 28 issue of the Journal of ...

User comments